Open AccessCentella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study
Author(s) -
JauShin Lou,
Dessislava Dimitrova,
Charles Murchison,
G. Arnold,
Heather Belding,
Nick Seifer,
Ngoc Anh Le,
Sarah B. Andrea,
Nora E. Gray,
Kirsten M. Wright,
Maya Caruso,
Amala Soumyanath
Publication year - 2018
Publication title -
esperienze dermatologiche
Language(s) - English
Resource type - Journals
eISSN - 2532-1056
pISSN - 1128-9155
DOI - 10.23736/s1128-9155.18.00455-7
Subject(s) - medicine , centella , placebo , diabetes mellitus , diabetic neuropathy , neuropathic pain , peripheral neuropathy , dysgeusia , randomized controlled trial , gastroenterology , anesthesia , surgery , adverse effect , endocrinology , traditional medicine , pathology , alternative medicine
Diabetic neuropathy (DN), a common complication of diabetes mellitus, results from hyperglycemia, poor microcirculation and attendant nerve damage. Currently available treatments relieve symptoms, but do not modify the neurodegeneration underlying DN. Centella asiatica (CA) triterpenes improved microcirculation in earlier clinical studies, and showed neurotropic effects in preclinical models suggesting a potential disease modifying effect in DN. This 52-week, randomized, double-blind, placebo-controlled trial examined the effects of CAST, a standardized CA extract containing triterpenes, on neuropathy symptoms in Type II diabetic subjects.